PROTEINA CO.,LTD. Third-party allotment of 151,886 convertible preferred shares at KRW 48,061 each
PAI summary · Not investment advice
PROTEINA CO.,LTD. will issue about 150,000 convertible preferred shares at KRW 48,061 each to investment funds, raising KRW 5.2 billion for facilities and KRW 2.1 billion for operations.
New shares · preferred
151,886 shares
Shares outstanding before offering: 11,105,148
Key facts
- Offering method
- Third-party allotment
- Shares outstanding before offering (common)
- 11,105,148 shares
- Issue price per share
- KRW 48,061
- Capital expenditure
- KRW 5.2 billionAI Biofoundry facility investment
- Working capital
- KRW 2.1 billionPPI Landscape platform R&D and in-house drug candidate development
- Payment date
- Nov 12, 2026
- Board resolution date
- Nov 4, 2026
- Lock-up
- Full lock-up for 1 year
- Conversion price per share
- KRW 48,061Conversion ratio 100%
- Convertible shares
- 151,886 sharesCommon shares
- % of total shares
- 1.35%
- Conversion period
- Nov 13, 2027 – Oct 13, 2031
- Call option limit
- 15% of the shares each investor subscribedExercisable every 3 months from 2027.11.13 to 2029.02.13
Commentary
AI commentary · Not investment advice
What happened
PROTEINA CO.,LTD. decided to raise money by selling new shares (a paid-in capital increase). The shares go only to selected investment partnerships and funds, not to existing shareholders. It will issue 151,886 convertible preferred shares (preferred shares that can later be turned into common shares). The price is KRW 48,061 per share. The largest allottee is Timefolio Bio Healthcare New Technology Investment Partnership No. 2, with 31,210 shares.
In the company's terms
The issue price is 2.23% above the reference share price of KRW 47,014. Before this offering, the company had 11,105,148 common shares. If all the preferred shares are converted, they equal 1.35% of total shares. KRW 5.2 billion will go to AI Biofoundry facilities. KRW 2.1 billion will fund platform research and in-house drug candidate development.
What changes for shareholders
Investors pay on November 12, 2026, and agreed not to sell the shares for 1 year. Conversion into common shares can be requested from November 13, 2027 to October 13, 2031. If the share price falls, the conversion price can be lowered, but not below KRW 33,643. The preferred shares receive a dividend of 1.0% a year on par value before common shares. The company also has a call option (a right to buy back part of the investors' shares). The limit is 15% of the shares each investor subscribed.
Earlier Material Event Report filings from this company
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.11.042026.11.04 | Material Event Report | KRW 29.2 billion |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist